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2ABSTRACT 
Blood Brain Barrier (BBB) permeability is frequently compromised in the course of diseases 
affecting the central nervous system (CNS). Sucrose is a low molecular weight, hydrophilic 
marker with low permeability at the naive BBB and therefore one of the widely used indicators 
of barrier integrity. Our laboratory recently developed a highly sensitive UPLC-MS/MS method 
for stable isotope labelled [13C12]sucrose in biological matrices. Correction of total brain 
concentration for contribution of intravascular space is required in such experiments in order to 
accurately measure BBB permeability, and it is often accomplished by vascular perfusion with 
buffer solutions prior to brain sampling. The purpose of the present study was to develop a 
UPLC-MS/MS method, which allows simultaneous analysis of two different stable isotope 
labeled sucrose variants, one of which can be utilized as a vascular marker. The first analyte, 
[13C12]sucrose, serves to quantify brain uptake clearance as a measure of BBB permeability, 
while the second analyte, [13C6]sucrose, is administered just before termination of the animal 
experiment and is considered as the vascular marker. [2H2]sucrose is used as the internal 
standard for both 13C labeled compounds. Because the majority of recent studies on CNS 
diseases employ mice, another objective was to validate the new technique in this species. The 
UPLC-MS/MS method was linear (r2≥0.99) in the tested concentration ranges, from 10 to 1,000 
ng/mL for both analytes in plasma, from 2 to 400 ng/g [13C12]sucrose in brain and from 10 to 
400 ng/g [13C6]sucrose in brain. It was also validated in terms of acceptable intra and inter run 
accuracy and precision values (n=5). The dual analyte technique was applied in a study in mice. 
One group received intravenous bolus injections of 10 mg/kg [13C12]sucrose at time 0, and 10 
mg/kg [13C6]sucrose at 14.5 min, and subsequent terminal blood and brain sampling was 
3performed at 15 min. For comparison, another group received an intravenous bolus dose of 10 
mg/kg [13C12]sucrose and was submitted to transcardiac perfusion with buffer after 15 min. We 
demonstrate that the two alternative techniques to correct for intravascular content deliver 
equivalent values for brain concentration and brain uptake clearance. 
Keywords: Blood-brain barrier; Vascular space correction; Pharmacokinetics; Stable isotope 
labeled sucrose
41. Introduction
The microenvironment within the central nervous system (CNS) needs to be tightly 
controlled for optimal function, because the composition of CNS extracellular fluid (also known 
as cerebrospinal fluid) is unique when compared to other tissues. The precise control of 
substances entering or leaving the CNS is maintained by the blood-brain barrier (BBB) [1, 2]. 
With the help of complex intercellular tight junctions between the endothelial cells, the BBB 
effectively restricts the passage of ions and polar compounds, resulting in high transendothelial 
electrical resistance and low paracellular permeability [3]. Impairment of the BBB is either the 
cause or a major pathophysiological consequence of many diseases affecting the CNS (i.e., 
ischemic stroke, neuroinflammatory and neurodegenerative disorders). Therefore, BBB 
permeability is considered one of the important parameters to be monitored in experimental 
and clinical studies of CNS disorders [4-6].
A range of BBB permeability markers is currently in use in experimental animal models, 
including Evans Blue, sodium fluorescein, horseradish peroxidase, sucrose, and inulin [7-9]. 
Among the drug-like low molecular weight agents, radiolabeled sucrose (e.g. [14C]sucrose) has 
long been considered the most accurate marker, explaining its frequent use [9]. We have 
recently introduced [13C12]sucrose as a superior marker substance, which is non-radioactive and 
can be quantified by a sensitive and highly specific LC-MS/MS technique [10-12]. The 
[13C12]sucrose technique has previously been validated in rats in our laboratory [10]. For an 
accurate measurement of the concentrations of the marker in the brain tissue, the method 
relies on removal of the marker from the brain vasculature by a brief vascular washout by 
transcardiac perfusion with buffer solution before tissue sampling.  However, it is difficult to 
5judge the completeness of vascular washout in an individual animal. Additionally, there are 
numerous variations in technical details how the perfusions are performed, e.g., with regard to 
total volume, duration, flow rate, temperature and composition of perfusion fluid, which may 
add to the experimental variability. 
An alternative is to include a second marker in the brain uptake experiments, which is 
injected just prior to the terminal sampling time. Although the application of a vascular marker 
that is physicochemically identical to the primary analyte has been advocated in the earlier BBB 
literature [13], emulation of this approach is rare and only few practical applications exist to 
date, likely due to the experimental effort required for any given analyte to reduce the concept 
to practice. Go and Pratt analyzed brain uptake of sodium ions using two radioisotopes with 
vastly different physical half-lives (22Na and 24Na), which allowed discrimination of the fractions 
of the two isotopes present in a tissue sample [14]. In an example from the other end of the 
molecular weight spectrum, Poduslo’s laboratory corrected the brain uptake of 
macromolecules by radioiodinating the same protein with either 125I or 131I, and one labeled 
species was used as a vascular marker [15]. 
The commercial availability of different stable isotope labeled versions of sucrose allows 
their simultaneous use as both the BBB permeability and brain vascular space markers. 
Therefore, the main purpose of this study was to develop a UPLC-MS/MS method to utilize one 
variant of [13C]sucrose as the permeability marker, another [13C]sucrose version as the vascular 
marker, and a third, deuterium labeled sucrose, as the internal standard. Selecting suitable 
combinations of mass transitions and settings of the mass detector allows simultaneous LC-
MS/MS quantification of the three sucrose variants, which co-elute at the identical retention 
6time from a BEH-amide UPLC column. Because mice are currently the most frequently used 
rodent model for studying the BBB, a secondary objective of our study was to validate the 
technique for use in mice, as opposed to our previous method for the use of [13C]sucrose in 
rats. Applying this approach in mice, we show that the brain concentration and permeability 
values of sucrose can be corrected equally well as achieved by buffer washout.
2. Materials and methods
2.1. Chemicals and reagents
[13C12]Sucrose (with all 12 carbons labeled with 13C isotope), [13C6]sucrose (with 6 of the 
carbons in the fructose moiety labeled with 13C Isotope) and [2H2]sucrose ([6,6'-2H2 fru]sucrose) 
were purchased from Omicron Biochemicals (South Hill Street South Bend, IN, USA). Analytical 
grade ammonium hydroxide, LC–MS/MS grade acetonitrile and water were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA). For anesthesia, isoflurane was purchased from Lloyd 
Laboratories (Shenandoah, IA, USA). Heparin solution was purchased from APP Pharmaceuticals 
(Schaumburg, IL, USA). All other chemicals were analytical grade and obtained from commercial 
sources.
2.2. Animals
Female C57Bl/6 mice, 8-10 weeks of age, body weight 24-27 g, were supplied by Jackson 
Laboratories (Bar Harbor, ME, USA) and used in the pharmacokinetic study. Mice had free 
access to standard rodent chow and water and were housed in an AAALAC-accredited animal 
7facility under controlled humidity and temperature conditions with a 12h light/12h dark cycle. 
The experimental protocols were approved by the Institutional Animal Care and Use Committee 
at Texas Tech University Health Sciences Center and conformed to current NIH guidelines.
2.3. Mass spectrometric and chromatographic conditions
Analyte detection was performed using an AB SCIEX QTRAP® 5500 triple quadrupole 
mass spectrometer (MS) attached to a Nexera UPLC system (Shimadzu Corporation). The UPLC 
system contained an autosampler (Sil-30AC), pumps (LC-30AD), a controller (CBM-20A), a 
degasser (DGA-20A5), and a column oven (CTO-30A). Data acquisition and quantification was 
done with the help of Analyst software. An Acquity BEH amide column (2.1 mm x 50 mm, 1.7 
µm; Waters , Milford, MA, USA) was used for chromatographic separation with isocratic elution 
in acetonitrile: water: ammonium hydroxide (72:28:0.1, v/v), at a flow rate of 0.2 mL/min. 
Column temperature was maintained at 45°C. Total run time per injection was 6 minutes. 
Electrospray ionization in negative mode was used as the ionization source. 
Optimization of mass spectrometer parameters for [13C12]sucrose and [13C6]sucrose was already 
shown in our previous study [10]. The mass spectrometer conditions for [2H2]sucrose were 
optimized to get optimum M−H−1 signal by continuous infusion of the standard solution with an 
infusion pump. The optimized mass spectrometer parameters were as follows: ion spray 
voltage, −4500 V; collision gas, high; curtain gas, 30 psi; temperature, 600°C; ion source gas 1 
(nebulizer gas), 55 psi; and ion source gas 2 (turbo gas), 55 psi. For [13C12]sucrose, the m/z 
transition 353 → 92 was selected. For [13C6]sucrose, the transitions 347 → 89 and 347 → 59 are 
8applicable, and the latter was preferable for brain matrix (as discussed below in section 3.2). 
The m/z transition 343 → 89 was selected for [2H2]sucrose.
2.4. Preparation of standard curves for the dual analytes
In preparing standard curves for the dual analyte application, [13C12]sucrose and 
[13C6]sucrose were considered as the analytes, whereas [2H2]sucrose was used as the internal 
standard. For plasma standard curves, blank mouse plasma was spiked with [13C12]sucrose and 
[13C6]sucrose stock solutions in water to get plasma concentrations of 1-100 µg/mL. The 
individual plasma calibration standards were then diluted 100-fold with water to produce 
concentrations within the range of 10-1,000 ng/mL, before being subjected to the sample 
preparation procedure detailed below. In case of the brain standard curve, blank brain tissue 
was homogenized in water (1:9) and both analytes were spiked into the homogenate to obtain 
concentrations ranging from 2 to 400 ng/mL for [13C12]sucrose and 10 to 400 ng/ml for 
[13C6]sucrose.
2.5. Sample preparation 
As mentioned above, plasma calibration standards and unknown samples were diluted 
100 times with LC-MS/MS grade water, and brain samples were homogenized in water (1:9) 
before analysis. Deproteination for all samples was achieved in a microcentrifuge tube by 
diluting at a ratio of 1:9 in acetonitrile: water (80:20) containing 10 ng/mL of internal standard. 
Precipitated samples were vortexed, followed by centrifugation at 20,000 g for 10 minutes. The 
supernatant was transferred into autosampler inserts. A sample volume of 5 µL was injected 
onto the UPLC column.
92.6. Method validation 
2.6.1. Selectivity
Selectivity of the method was ensured by running blank matrix samples containing no 
analyte. Also in order to ensure that there is no interference in among the analyte transitions, 
neat samples containing single analytes without any matrix prepared in mobile phase 
composition were run using the method defined above.
2.6.2. Accuracy and precision
The accuracy and precision of the method was determined through inter and intra-day 
runs, where quality control samples were evaluated against calibration curves. For calculation, 
five repeats of low, medium, and high concentrations were analyzed. The accuracy was 
calculated as percentage of measured concentration over nominal concentration. Precision was 
calculated as percentage of relative standard deviations (R.S.D.). The acceptable inter and intra-
run limits for the accuracy were set at 85–115% for the middle and high concentrations and 80–
120% for the low concentration. The acceptable precision values were 15% (medium and high 
concentrations) or 20% (low concentration) [16].
2.6.3. Linearity 
The linearity of calibration curves was evaluated by the coefficient of variation (r2) of the 
linear regression analysis of the concentration-response data using a weight of 1/x, where x is 
the concentration. Weighting by 1/x is superior to analysis with equal weights, because the 
latter results in greatly diminished accuracy and high variability at low concentrations.
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2.6.4. Recovery 
Recovery of the analytes was checked and found not to be subject to matrix effects in 
the previously developed method for both [13C12]sucrose as well as [13C6]sucrose [10]. In the 
dual analyte method, when [2H2]sucrose is considered as the new internal standard, we 
expected that the recovery of the analytes [13C12]sucrose and [13C6]sucrose will remain similar 
to the results described previously, since all of the analytes and the new internal standard are 
stable labelled isotopes of the same chemical entity. Nevertheless, a recovery study of the 
analytes was performed in all of the concerned matrices at low, medium and high-level 
concentrations as follows (n = 5): In case of [13C12]sucrose, the concentrations were, 100 and 
1000 ng/mL for plasma matrix and 2, 50 and 400 ng/mL for brain samples. In case of 
[13C6]sucrose, the concentrations were 10, 100 and 1000 ng/mL for plasma matrix and 10, 50 
and 400 ng/mL for brain samples. Five replicate samples were prepared in each of the 
concerned matrices, and samples with equivalent concentrations prepared in water (instead of 
matrix) were used as references. The samples and references were subjected to the sample 
preparation method described above, and the peak areas of [13C12]sucrose, [13C6]sucrose and 
the internal standard [2H2]sucrose were determined. Recovery was calculated as percent of the 
ratio of peak areas Sample/Reference, where sample refers to the matrix and reference to 
water (neat sample), respectively. 
2.6.5. Freeze thaw stability
We subjected neat samples of the analytes at a concentration of 500 ng/mL to three 
freeze/thaw cycles. Samples were stored at -80°C and thawed at room temperature for one 
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hour, replicating experimental conditions. Concentration of the analytes in the neat samples 
was compared against a standard curve.
2.6.6 Long-term, storage stability of unprocessed and short-term stability of processed 
samples
Long term, storage stability was checked for the diluted plasma samples and brain 
homogenates at -80°C.  Quality control samples at low, medium, and high concentrations of 
analytes in the brain and plasma (n = 3) were stored at -80°C for one month and 5 months, 
respectively. The stored samples were then compared against standards in order to assess 
stability. Similarly, for the processed sample stability, quality control samples in both matrices 
(n = 3) were subjected to the sample preparation method above, and the supernatant after 
protein precipitation was stored at 4°C for 24 hours before injection by the autosampler. 
2.7. Application of the method
A pharmacokinetic study was conducted in two groups of anesthetized C57BL/6 mice. 
Isoflurane (4% for induction, 1.5-2% v/v for maintenance) in 70% nitrous oxide / 30% oxygen at 
a flow rate of 1 L/min was applied via a silicone face mask. The jugular veins were bilaterally 
exposed by skin incisions at the neck for IV injections on one side and blood sampling from the 
contralateral side. 10 mg/kg [13C12]sucrose in saline was injected as an IV bolus dose. Blood 
samples (30 µL) were collected at 0.5, 1, 2, 5, 10, and 15 min after injection to allow for analysis 
of the plasma concentration time curve in each individual animal. In one group of animals 
(Washout Group, n = 6), the thorax was opened immediately after the 15 min blood sample, 
and vascular perfusion was performed via the left ventricle of the heart at a flow rate of 2 
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mL/min with a total of 20 ml phosphate buffered saline (pH 7.4) at room temperature, using a 
Harvard syringe pump. At the start of perfusion both jugular veins were cut open to facilitate 
outflow of blood from the brain and to visually confirm that the outflowing perfusion fluid was 
clear of blood by the end of the perfusion, when brain was sampled. In the second group of 
animals (Vascular Marker Group, n = 7), an IV bolus dose of [13C6] sucrose (10 mg/kg in saline) 
was injected at 14.5 min, 30 sec prior to the terminal sampling time point. These animals were 
euthanized by decapitation immediately after the terminal blood sample had been collected. 
Blood samples were centrifuged and plasma was separated. Brains were removed from the 
skull, cleaned of meninges, and the forebrains (without olfactory bulbs, cerebellum or brain 
stem) were weighed and flash frozen in isopentane/dry ice. At the end of each experimental 
day, brain and plasma samples were homogenized/diluted in water as described in the sample 
preparation step and stored at -80°C until the day of measurement by the UPLC-MS/MS system. 
Brain tissue concentration values in the Washout Group, which had undergone buffer washout, 
were considered as corrected for intravascular content, ( ). The corresponding values of 𝐶
𝐶12
𝑏𝑟 ‒ 𝑐𝑜𝑟𝑟
corrected brain concentrations in the Vascular Marker Group, receiving the vascular marker 
injection without buffer washout, were determined as follows:
 (1)𝐶
𝐶12
𝑏𝑟 ‒ 𝑐𝑜𝑟𝑟 =  (𝑉𝑑 ‒ 𝑉0) × 𝐶𝐶12𝑝𝑙1 ‒ 𝑉0
where Vd is apparent volume of distribution of the BBB permeability marker, [13C12]sucrose, V0 




(15 min) plasma concentration of [13C12]sucrose. The Vd and V0 values were estimated using the 
following two equations. 
 (1a)𝑉𝑑 = 𝐶𝐶12𝑏𝑟 /𝐶𝐶12𝑝𝑙
(1b)𝑉0 = 𝐶𝐶6𝑏𝑟/𝐶𝐶6𝑝𝑙





sucrose, respectively, at the terminal sampling time (15 min), and  is the terminal plasma 𝐶
𝐶6
𝑝𝑙
concentration of [13C6] sucrose at 15 min.
Values for brain uptake clearance, Kin, also known as the permeability-surface area 
product, were calculated using the following equation [17] based on either uncorrected ( ) 𝐶
𝐶12
𝑏𝑟
or corrected ( ) brain concentrations of [13C12]sucrose:𝐶
𝐶12
𝑏𝑟 ‒ 𝑐𝑜𝑟𝑟
(2)𝐾𝑖𝑛 = 𝐶𝐶12𝑏𝑟 /𝐴𝑈𝐶𝑇0
𝐾𝑖𝑛 ‒ 𝑐𝑜𝑟𝑟 = 𝐶 𝐶12𝑏𝑟 ‒ 𝑐𝑜𝑟𝑟/𝐴𝑈𝐶𝑇0
where AUC0T is the area under the plasma concentration time curve from time 0 to the terminal 
sampling time (15 min) for [13C12]sucrose. AUC was determined by the linear-logarithmic 
trapezoidal method using the non-compartmental analysis (NCA) module in Phoenix WinNonlin. 
3. Results
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3.1. MS parameter optimization of [2H2]sucrose
Figure 1 depicts the mass spectra with precursor and product ions for [13C12]sucrose (a), 
[13C6]sucrose (b), and [2H2]sucrose (c) after optimization of the MS parameters. Similar to our 
previous report [10], the mass spectra obtained for the 2 13C-labelled isotopes of sucrose 
showed m/z transitions of 353>92 and 347>89 for [13C12]sucrose (Fig. 1a) and [13C6]sucrose (Fig. 
1b), respectively. In case of [13C6]sucrose, the m/z transition of 347>59 is also a viable 
alternative (Fig. 1b). For the newly optimized [2H2]sucrose, the m/z transition of 343>89 was 
found to be the best transition in terms of signal to noise ratio (Fig. 1c). In the previously 
described single analyte method, [13C6]sucrose was utilized as the internal standard. However, 
repeat injections of the same concentrations of [13C6]sucrose and [2H2]sucrose (Fig. 2) showed 
that [13C6]sucrose provided higher sensitivity (larger peak areas and signal to noise ratios) 
compared to [2H2]sucrose. As a consequence, we chose [13C6]sucrose as the second analyte (i.e., 
vascular marker) and [2H2]sucrose as the internal standard. 
3.2 Selectivity
Single analyte neat samples prepared in water showed no cross-channel interference 
between transitions in the absence of matrix (Fig. 3). Chromatograms of samples containing 
blank, lowest standards and internal standard in mouse plasma and mouse brain are depicted 
in Fig. 4. The matrix samples were found to be acceptable without any interference except for 
transition 347>89 of [13C6]sucrose, which had an interfering peak in the blank brain samples at 
the same retention time as the analyte (approx. 2.1-2.2 min). The transition 347>59 had a peak 
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at retention time approx. 2.6 minute in brain matrix, which does not interfere with the analyte 
peak at retention time of 2.1 min, and hence was chosen for measurement of brain samples. 
3.3 Accuracy and precision
The results of the inter and intra run accuracy and precision experiments in plasma 
and brain samples are presented in Tables 1 and 2, respectively. Accuracy and precision values 
of the quality control samples in low, middle and high-level QCs across both tested matrices 
were found to be within the acceptable limits. 
3.4. Linearity
Calibration curves in both tested matrices across all intra and inter assay runs were 
found to be linear with r2>0.99. 
3.5. Recovery
The recoveries (mean ± SD) of [13C12] and [13C6]sucrose from the plasma and brain 
samples at all the concentrations (n = 5) were quantitative. Recoveries of [13C12]sucrose from 
plasma samples at nominal concentrations of 10, 100, and 1000 ng/mL were 104 ± 9, 97.5 ± 4.5, 
and 105 ± 8 percent, respectively. Recoveries of [13C6]sucrose from plasma at the same 
concentrations were 99.6 ± 13.6, 99.0 ± 6, and 106 ± 9 percent. For [13C12]sucrose in brain 
homogenate at 2, 50, and 400 ng/mL, recoveries were 94.1 ± 4.2, 102 ± 3 and 100 ± 1 percent, 
respectively. For [13C6]sucrose in brain homogenate at 10, 50, and 400 ng/mL, recoveries were 
108 ± 11, 106 ± 4 and 99.2 ± 2.7 percent, respectively. 
3.6. LLOD and LLOQ
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As apparent from Fig. 4 and Tables 1 and 2, our method can accurately and precisely 
measure [13C12]sucrose and [13C6]sucrose at the lowest concentrations of the respective 
calibration curves (10 ng/mL in diluted plasma for both analytes, 2 ng/g brain for [13C12]sucrose 
and 10 ng/g for [13C6]sucrose). Based on a signal to noise ratio of ≥ 3, the LLOD of the assay on 
column is 0.1 pg, as previously reported [10] 
3.7. Stability
Results from the long-term, storage stability of unprocessed and short-term stability of 
processed samples are shown in Table 3. Additionally, Fig. 5 depicts the freeze thaw stability 
data. All data were found to be within specifications. Analytes were found to be stable in 
plasma and brain matrix over long term (Table 3). Also, processed samples stability data suggest 
that the processed samples could be stored at 4oC for up to 24 hours before analysis (Table 3). 
However, we found that at 48 hours the peak shape degraded, indicating a storage time of 
processed samples beyond 24 hours may not be suitable (data not shown).
3.8 Application of the method
The results of the pharmacokinetic study are depicted in Fig. 6. All concentrations of 
analytes [13C12]sucrose or [13C6]sucrose measured from brain and plasma samples fell within the 
range of the respective standard curves. As expected, plasma concentration – time curves in 
the two groups of mice were similar (Fig. 6a), and the areas under curve from 0 to 15 min were 
not significantly different (unpaired, two-tailed, t-test).  After considering the dilution factor of 
10 for brain samples, the average values (±SD) of brain concentrations (Fig. 6b) were as follows: 
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Brain concentration of the BBB permeability marker [13C12]sucrose in the Washout group was 
129 ± 26.0 ng/g; brain concentration of [13C12]sucrose in the Vascular Marker group was 265 ± 
42 ng/g before correction for intravascular content, and 138 ± 27 ng/g after correction (see Fig. 
6b). Comparison of the corrected brain concentrations (washout vs. vascular marker correction) 
showed no significant difference (p = 0.59, unpaired, two-tailed t-test). Similarly, the values for 
brain uptake clearance, Kin-corr, were almost identical under both techniques: 0.257 ± 0.053 µL 
min-1 g-1 vs. 0.260 ± 0.047 µL min-1 g-1 for the Washout and Vascular Marker groups, 
respectively, as depicted in Fig 6c. Without correction for the intravascular content, the 
estimate of apparent Kin in the Vascular Marker group would be 0.501 ± 0.064 µL min-1 g-1. The 
estimated intravascular plasma space, V0, as represented by the apparent volume of 
distribution of the vascular marker, was 9.12 ± 1.89 µL g-1.
4.  Discussion
The results of this study represent an extension and refinement of the previously 
described method [10] for measurement of [13C12]sucrose in brain and plasma by UPLC-MS/MS. 
Sample preparation and quality control experiments demonstrated that measuring stable 
labelled isotopes of sucrose in plasma and brain matrices from mice can be performed with 
similar assay quality as in rats [10]. Accuracy and precision values for the lowest calibration 
standard (Tables 1 and 2), along with linearity of the standard curves, were all well within the 
defined specifications. Similar to previous findings [10, 18], the recovery from the matrices 
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throughout the concentration ranges covered by the standard curves was found to be almost 
quantitative for both [13C12]sucrose and [13C6]sucrose.
The dual analyte method with a vascular marker is particularly attractive in the case of 
sucrose, because several isotopically labelled variants of sucrose are readily commercially 
available. As they are chemically equivalent and co-elute from a suitable stationary phase, such 
as the BEH amide column used here, variation of detector signal due to confounding factors, 
like differences in ion suppression between analytes and/or internal standard, is expected to be 
minimal. As shown in Fig. 4, equivalent mass transitions for all three sucrose isotopes can be 
chosen for analysis in the various matrices, with the exception of [13C6]sucrose in brain. Blank 
brain matrix showed a peak at the same retention time as the analyte at transition m/z 347>89. 
Transition 347>59 m/z provided a better signal to noise ratio and was used for quantification of 
[13C6]sucrose in brain matrix. Since the in vitro stability of [13C12]sucrose in cell culture media as 
well as brain homogenate was tested in a previous study for up to 3 hours [12], in this study we 
also included processed samples stability, long term stability as well as freeze thaw stability in 
order to confirm that the analytes stay stable in the applied conditions for specified periods of 
time. Since both analytes are different stable isotope labeled versions of the same molecule, we 
can imply that the stability for [13C12]sucrose is also valid for [13C6]sucrose.
We found that for physiological applications, such as brain uptake experiments, the dual 
analyte technique is equally effective as buffer perfusion. As demonstrated in the mice 
receiving a vascular marker injection, the intravascular content, if left uncorrected, would cause 
significant overestimation of brain concentration and Kin by a factor of almost 2 in the present 
experiments with brain sampling at 15 min (Fig. 6b and c). At shorter terminal sampling time 
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points that error would be even more pronounced, because plasma concentrations are still 
higher (Fig. 6a), and therefore the ratio of vascular content to total brain concentration is also 
higher. Because the vascular marker itself is subject to brain uptake during the brief interval 
between injection and brain sampling, intravascular volume is slightly overestimated, and 
correspondingly, the calculated values of corrected brain concentration and Kin for the 
permeability marker [13C12]sucrose, would be slightly underestimated. However, as shown by 
our data, that error is too small to result in significant differences when compared to the 
vascular washout procedure. Moreover, the V0  value of 9.12 ± 1.89 µL g-1 , as measured with 
[13C6]sucrose in the present study, is almost identical to the brain plasma volume of 9.3 ± 1.1 
µL g-1 as determined by our laboratory with radiolabeled IgG in a previous study in mice [19], 
and it falls into the middle of the range of values reported in the literature for rodents [20].
There are distinct practical advantages of the correction method by vascular marker 
administration over the washout method: It is technically simpler, and collection of brain tissue 
is feasible within seconds after the terminal blood sampling, rather than being delayed several 
minutes by thoracotomy and perfusion (e.g., over 10 min in the present study). Additionally, 
rapid sampling is important when, in addition to measurement of BBB permeability, parts of the 
brain samples were to be used for measurement of other analytes that may be subject to rapid 
degradation, such as neurotransmitters or metabolites. 
5. Conclusions
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In conclusion, the previously described UPLC-MS/MS method with a single analyte has 
been refined by the addition of a second stable isotope labeled sucrose variant, which serves as 
a vascular marker. The method allows measurement of both analytes in the same sample in a 
single run. This technique simplifies correction for intravascular plasma space in brain uptake 
experiments with sucrose and makes a vascular washout step dispensable.
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Table 1
Intra- and inter-run values for accuracy and precision of lowest, middle and highest concentrations of 
[13C12]sucrose and [13C6]sucrose in the calibration curves in mouse plasma (n = 5).












[13C12]sucrose 10 10.1 101 2.68 9.76 97.6 3.18
100 97.9 97.9 1.34 97.1 97.1 1.18
1000 984 98.4 1.69 980 98.0 0.98
[13C6]sucrose 10 9.82 98.2 6.29 10.4 104 2.69
100 96.0 96.0 2.27 96.2 96.2 2.18
 1000 983 98.3 3.45 986 98.6 3.38
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Table 2
Intra-day and inter-day run values for accuracy and precision of lowest, middle and highest concen-
trations of [13C12]sucrose and [13C6]sucrose in the calibration curves in mouse brain homogenate (n = 5)












[13C12]sucrose 2 1.98 99.1 3.52 1.98 99.3 7.23
50 48.3 96.6 1.08 49.5 98.9 1.84
400 372 92.9 3.71 416 104 4.24
[13C6]sucrose 10 10.1 101 6.06 9.96 99.6 7.67
50 48.2 96.3 2.72 48.8 97.6 2.25
 400 380 95.0 5.05 414 103 3.11
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Table 3
Stability of [13C12]sucrose during long-term storage (5 months for plasma and 1 month for brain 
homogenate, -80°C) of unprocessed and short-term storage (24 hr for both plasma and brain 
homogenate, 4°C) of processed samples (n = 3).












Plasma 10 9.68 96.8 3.22 10.0 100 1.91
100 102 102 1.72 98.4 98.4 2.65
1000 1000 100 2.62 1040 104 2.52
2 1.98 98.8 9.94 2.00 100 8.41
50 49.2 98.4 2.79 48.1 96.3 1.92
Brain 
homogenate
400 389 97.3 5.46 423 106 2.94
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Legends for Figures
Figure 1: Mass spectra with precursor and product ions for [13C12]sucrose (a), [13C6] Sucrose (b), and 
[2H2]sucrose (c) 
Figure 2: Comparison of peak areas of [2H2]sucrose and [13C6]sucrose obtained in repeated injections 
under optimized detection conditions (mean ± SD, n=15). [13C6]sucrose produces consistently higher 
peak areas and achieves higher sensitivity. 
Figure 3: Chromatograms of single analyte neat samples of [13C12] Sucrose, [13C6] Sucrose and [2H2] 
Sucrose, prepared in LC-MS/MS grade water in all considered transitions. 
Figure 4: Chromatograms of blank matrices, lowest calibration standard and internal standard in Plasma 
(Panel a) and Brain Matrix (Panel b).
Figure 5: Freeze thaw stability of [13C12] sucrose and [13C6] sucrose in LC-MS/MS grade water. Columns 
and error bars represent mean and SD values, respectively (n=3).
Figure 6: (a) Pharmacokinetic profile for [13C12] Sucrose up to 15 minutes in mouse plasma (mean ± SD, 
n=6). (b) Differences in brain concentrations of [13C12] Sucrose with or without correction by vascular 
marker (c) Differences in Kin values of [13C12] Sucrose with or without correction by vascular marker.






